Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

Hidden Business in Cyient Limited: The Semiconductor Pivot

Sterlite Technologies: Project Lakshya Raises The Stakes

Marksans Pharma: Europe- The Next Growth Engine!

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Artemis Medicare Services / Equity Bottom-Up

<ul>
<li>Gurugram remains the earnings engine, with occupancy improving to 65.7% and Tower IV offering 200+ additional beds for future growth. </li>
<li>Raipur has commenced operations, while South Delhi adds a 650+ bed asset-light opportunity, significantly expanding Artemis Medicare’s growth runway. </li>
<li>Q1 FY27 revenue grew 12.7% YoY, while PAT rose 48.3%, supported by stronger Gurugram margins, higher ARPOB and operating leverage</li>
</ul>


Gurugram remains the earnings engine, with occupancy improving to 65.7% and Tower IV offering 200+ additional beds for future growth. 
Raipur has commenced operations, while South Delhi adds a 650+ bed asset-light opportunity, significantly expanding Artemis Medicare’s growth runway. 
Q1 FY27 revenue grew 12.7% YoY, while PAT rose 48.3%, supported by stronger Gurugram margins, higher ARPOB and operating leverage


How Artemis Medicare Is Scaling from a Flagship Hospital to a Multi-Region Platform?